The TRT market has clearly stabilized - and Axiron appears to be making a gradual uptick... will hold off calling this a return to growth until another couple of quarter results.
They are starting to focus on expanding the pipeline - the messaging is better and more positive... the idea that this is a fully funded biotech is a good one and they do have some interesting IP / areas of focus here.... Now its time to deliver on these!!!
Add to My Watchlist
What is My Watchlist?
